

Centers for Disease Control and Prevention

National Center for Immunization and Respiratory Diseases




Hepatitis B and Hepatitis B Vaccine

1

Disease

Hepatitis B Virus

- Hepadnaviridae family (DNA)
- Numerous antigenic components
- May retain infectivity for more than 7 days at room temperature



Hepatitis B Virus Infection

257 million
chronic infections
worldwide

**850,000–
2.2 million**
US chronic
infections

Causes
50%
of hepatocellular
carcinomas

786,000
deaths
worldwide

Hepatitis B Epidemiology

- **Reservoir** Human
- **Transmission** percutaneous (i.e., puncture through the skin) or mucosal contact with infectious blood or body fluids (e.g., semen, saliva)
- **Communicability** 1-2 months before and after onset of symptoms
Persons with either acute or chronic HBV infection with HBsAg present in blood

Hepatitis B Clinical Features

- Incubation period 60-150 days (average 90 days)
- Nonspecific prodrome of malaise, fever, headache, myalgia
- Children < 5 years and newly infected immunosuppressed adults generally asymptomatic
 - 30%–50% of persons aged ≥ 5 years have signs and symptoms

Hepatitis B Complications

- Fulminant hepatitis (<1%)
- Hospitalization
- Cirrhosis
- Hepatocellular carcinoma
- Death

Risk Factors for Hepatitis B


- Injection drug use
- 2 or more sexual partners
- Men who have sex with men
- Household contacts of persons with HBV
- Developmentally disabled persons in long-term-care facilities
- Correctional facilities
- Persons at risk for occupational exposure to HBV
- Hemodialysis patients
- Persons with HCV infection
- Persons with chronic liver disease
- Travelers to countries where HBV is endemic
- Persons with HIV
- Persons with Diabetes



Chronic Hepatitis B Virus Infection

- **80-90% of persons infected during infancy**
- **30% of persons infected before age 6 years**
- **1-12% of persons infected as an older child or adult**
- **Approximately 25% of persons chronically infected during childhood and 15% chronically infected after childhood will die prematurely from cirrhosis or liver cancer**

Risk of Chronic HBV Infection



Chronic Hepatitis B Virus Infection – 4 Phases

■ Immune tolerant

- Minimal or no hepatic inflammation or fibrosis

■ Immune active

- Hepatic inflammation with or without fibrosis


■ Immune inactive

- Improvement of hepatic inflammation and fibrosis

■ Reactivation

- Active hepatic inflammation with or without fibrosis

Hepatitis B Perinatal Transmission*



*in the absence of post exposure prophylaxis

Strategy to Eliminate Hepatitis B Virus Transmission— United States

■ Prevent perinatal HBV transmission

- Routine testing of all pregnant women for HBsAg
 - Prophylaxis (HepB vaccine and HBIG) for infants born to HepB surface antigen (HBsAg) positive women
 - HBV DNA testing for HBsAg positive women and antiviral therapy if HBV DNA is >200,000 IU/mL

New!

■ Universal vaccination of all infants at birth

■ Routine vaccination of previously unvaccinated children and adolescent (<19 years of age)

■ Vaccination of adults at risk for HBV infection

2

Vaccine

Hepatitis B-Containing Vaccine Products*

Vaccine product	Age indications
Single-component vaccines	
Engerix-B	
Pediatric formulation	Birth–19 years
Adult formulation	20 years and older
Recombivax HB	
Pediatric formulation	Birth–19 years
Adult formulation	20 years and older
Hepelisav-B	18 years and older
Combination vaccines	
Pediarix–DTaP, IPV and HepB vaccines	6 weeks–6 years
Twinrix–HepA and HepB vaccines	18 years and older

*ACIP does not state a preference for vaccine product versus another if the patient is eligible for more than 1 product

Recommended Dosage of HepB Vaccine

	Recombivax HB Dose (mcg)	Engerix-B* Dose (mcg)	Heplisav-B Dose (mcg)
Children: Birth through 19 years	0.5 mL (5)	0.5 mL (10)	N/A: ≤ 17 yrs 0.5 mL (20): ≥ 18 yrs
Adults: 20 years and older	1.0 mL (10)	1.0 mL (20)	0.5 mL (20)

*Pediatrix contains the pediatric formulation of Engerix-B

*Twinrix contains the adult formulation of Engerix-B

† Heplisav-B approved for use in persons 18 years of age or older

HepB Vaccine

	Recombivax HB Dose (mcg)	Engerix-B* Dose (mcg)	Heplisav-B Dose (mcg)
Composition	Recombinant HBsAg	Recombinant HBsAg	Adjuvanted Recombinant HBsAg
Efficacy	95% (Range, 80%–100%)	95% (Range, 80%–100%)	90%–100%
Schedule	3 doses	3 doses	2 doses
Route	IM	IM	IM

*Pediatrix contains the pediatric formulation of Engerix-B

*Twinrix contains the adult formulation of Engerix-B

Combination Vaccines

■ **Pediarix DTaP/IPV/HepB**

- Ages: 6 weeks through 6 years
- Routine schedule: 2, 4, 6 months of age
- Approved for dose 1, 2, 3 of Hep B (Do NOT use for the birth dose)

■ **Twinrix HepA/HepB**

- Ages: 18 years of age and older
- Routine schedule: 3 doses at 0, 1, 6 months, or
- 0, 7, 21- 30 days and a booster dose at 12 months
- Each dose of Twinrix contains an adult dose of hepatitis B vaccine
- A HepB series started with Twinrix can be complete with single antigen HepB vaccine and vice versa

3

**Clinical
Considerations**

ACIP HepB Vaccine Recommendations: Pediatric

- Routinely recommended for all children birth through 18 years of age
- Vaccinate previously unvaccinated children and those missing doses

Vaccine	Birth	1 mo	2 mos	4 mos	6 mos	9 mos	12 mos	15 mos	18 mos	19-23 mos	2-3 yrs	4-6 yrs	7-10 yrs	11-12 yrs	13-15 yrs	16 yrs	17-18 yrs
Hepatitis B (HepB)	1 st dose	2 nd dose			← 3 rd dose →												

HepB Schedule: Routine Infant


Dose ⁺	Routine Age
Dose 1	Birth [§]
Dose 2	1- 2 months
Dose 3 ⁺	6-18 months*

§The birth dose of single-component Hepatitis B vaccine should be administered within 24 hours of birth for medically stable infants weighing $\geq 2,000$ grams born to hepatitis B surface antigen (HBsAg)-negative mothers.

*Infants whose mothers are HBsAg+ or whose HBsAg status is unknown should receive the third dose at 6 months of age

+An additional dose at 4 months is acceptable if the clinician prefers to use a combination vaccine that contains hepatitis B vaccine


HepB Schedule: Minimum Age and Intervals



Pediarix Schedule Considerations

Can be given to infants who received HepB at birth = 4 doses*

Do NOT use for the birth dose



6 months is the minimum age for the last dose

*An additional dose at 4 months is acceptable if the clinician prefers to use a combination vaccine that contains hepatitis B vaccine

Birth Dose Considerations: Babies Weighing 2000 grams or more

HBsAg **NEGATIVE**
mother



Administer HepB
vaccine within
24 hours of birth

HBsAg **POSITIVE**
mother



Administer HepB
vaccine and HBIG*
within 12 hours of birth

HBsAg **UNKNOWN**
mother



Administer HepB
vaccine within 12 hours
of birth and test to
determine mother's
status ASAP

*Administer HepB vaccine and HBIG in separate limbs

Birth Dose Considerations: Babies Weighing Less Than 2000 grams

HBsAg **NEGATIVE**

mother



Administer HepB vaccine at hospital discharge or at 1 month of age

HBsAg **POSITIVE**

mother



Administer HepB vaccine and HBIG* within 12 hours of birth

HBsAg **UNKNOWN**

mother



Administer HepB vaccine within 12 hours of birth. Give HBIG, if the mother's HBsAg status cannot be determined within 12 hours of birth*

*Administer HepB vaccine and HBIG in separate limbs

Medical Considerations: Treating Infants Whose Mother is Hepatitis B Surface Antigen **POSITIVE**

- **Administer HepB vaccine and HBIG within 12 hours of birth**
 - HepB vaccine and HBIG can be administered at the same time
 - HepB and HBIG are both IM injections
 - Administer in different limbs
- **Complete vaccination series at 6 months of age**
 - 1st dose does not count when administered to infants weighing less than 2000 grams
- **Test for response after completing a 3-dose series at 9 through 12 months of age**

Medical Considerations: Treating Infants Whose Mother is Hepatitis B Surface Antigen **UNKNOWN**

- **Infants born to women without HBsAg testing results but other evidence suggests maternal HBV infection exists, administer both HepB and HBIG within 12 hours of birth**
- **Test mother for HBsAG status as soon as possible**
 - Infants weighing 2000 grams or more: If mother is determined to be hepatitis B surface antigen positive give HBIG as soon as possible, but no later than age 7 days
 - Infants weighing less than 2000 grams: If the mother tests positive or HBsAG status can not be determined, administer HBIG within 12 hours of birth

Serologic Testing and Children

■ **Prevaccination serologic testing is:**

- Not indicated before routine vaccination of infants or children
- Recommended for all persons born in Africa, Asia, the Pacific Islands, and other regions with HBsAg prevalence of 2% or higher

■ **Postvaccination serologic testing is:**

- Not routinely recommended following vaccination of infants, children, and adolescents
- Recommended for infants born to HBsAg+ women

ACIP HepB Vaccine Recommendations: Adult

- Vaccination recommended unvaccinated adults at risk for HBV infection and adults requesting protection from HBV infection
 - Acknowledgement of a specific risk factor not required vaccination

Vaccine	Pregnancy	Immuno-compromised (excluding HIV infection)	HIV infection CD4 count		Asplenia, complement deficiencies	End-stage renal disease, on hemodialysis	Heart or lung disease, alcoholism ¹	Chronic liver disease	Diabetes	Health care personnel ²	Men who have sex with men	
			<200	≥200								
HepB												2 or 3 doses depending on vaccine

Adults at Risk for HBV Infection

- Hepatitis C virus infection
- Chronic liver disease
- HIV infection
- Sexual exposure risk

* Persons with more than one sex partner during the previous 6 months

Adults at Risk for HBV Infection

- **Current or recent injection drug use**
- **Percutaneous or mucosal risk for exposure to blood**
- **Incarcerated persons**
- **Travel in countries with high or intermediate endemic hepatitis B**

* Persons with more than one sex partner during the previous 6 months

HepB Schedule: Adult Recombivax HB or Engerix-B

Dose	Routine Interval	Minimum Interval
Dose 1	---	---
Dose 2	1 month	4 weeks
Dose 3	6 months	8 weeks <i>and</i> at least 16 weeks from Dose 1

Heplisav-B (HepB-CpG)

Storage

Store in the refrigerator between 2°C and 8°C (36°F and 46°F)

Ages

18 years of age and older

Schedule

Administer 2 doses separated by 4 weeks

Administration

Intramuscular (IM) injection in the deltoid
Can be administered at the same clinical visit as other vaccines. Administer in separate injection sites, 1 inch apart (if possible)

Contraindication


History of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of Heplisav-B, including yeast

Additional Heplisav-B Considerations

- **2-dose HepB series only applies when BOTH doses are Heplisav-B, administered at least 4 weeks apart**
 - Any 2 doses of Heplisav-B separated by 4 weeks is considered complete, even if the patient has had other HepB vaccine products
- **Until safety data are available for Heplisav-B, providers should vaccinate pregnant women needing HepB vaccination with Engerix-B or Recombivax HB**

Scenarios

1.



HepB
Engerix-B or RecombivaxHB
01/01/2018



HepB-CpG
Heplisav-B
02/01/2018



HepB-CpG
Heplisav-B
03/01/2018

Completed series
No additional doses
are needed

2.



HepB
Engerix-B or RecombivaxHB
01/01/2018



HepB-CpG
Heplisav-B
02/01/2018



HepB
Engerix-B or RecombivaxHB
05/01/2018

Completed series
No additional doses
are needed

Diabetes Mellitus

- **Compared with adults without diabetes, adults with diabetes have a 60% higher prevalence of past or present HBV infection and twice the odds of acquiring acute HBV**
 - Possibility of a higher case-fatality proportion among persons with diabetes acutely infected with HBV
- **ACIP recommends HepB vaccination for persons with diabetes mellitus aged <60 years and persons with diabetes mellitus aged ≥60 years at the discretion of the treating clinician**
 - No preference for any of the available vaccines

Dialysis

- **Hepatitis B vaccination is recommended for susceptible hemodialysis patients**
- **Hepatitis B vaccine is also indicated for patients whose renal disease is likely to lead to dialysis or transplantation**

Dialysis

- **For patients undergoing hemodialysis and for other immunosuppressed patients, higher vaccine doses or increased number of doses are required**
 - Special formulations of the vaccines are now available for such persons (Recombivax HB, 40 µg/mL, Energix_B, 40 µg/mL)
- **If an adult patient begins the vaccine series with a standard dose before beginning hemodialysis treatment, then moves to hemodialysis treatment before completing the series, complete the series using the higher dose recommended for hemodialysis patients**

ACIP HepB Vaccine Recommendations: Healthcare and Public Safety Personnel



- All healthcare personnel (HCP) whose work-, training-, and volunteer-related activities involve reasonably anticipated risk for exposure to blood or body fluids should be assessed for evidence of immunity to hepatitis B.

Evidence of Immunity for HCP =

Written documentation of a complete HepB vaccine series

AND

Subsequent documented anti-HBs ≥ 10 mIU/mL


Common Clinical Scenarios for HCP

- **Documentation of complete series AND documented positive titer**
- **Unvaccinated (or incomplete series)**
- **Documentation of complete series but no documented positive titer**


Documentation of complete vaccine series AND documented positive titer

- HCP considered immune
- **NO** additional serologic testing or vaccine “booster” doses
- Advise the person to keep a copy of the vaccine record and positive titer FOREVER


Unvaccinated HCP (or incomplete vaccine series)



Documentation of complete vaccine series but no documented positive titer



Documentation of complete vaccine series but no documented positive titer (2)



Persistent Nonresponse to HepB Vaccine

- Less than 5% of vaccinees do not develop anti-HBs after 6 valid doses
- May be nonresponder or “hyporesponder”
- Check HBsAg status
- If exposed, treat as nonresponder with postexposure prophylaxis

HCP and Postexposure Management

TABLE 5. Postexposure management of health care personnel after occupational percutaneous or mucosal exposure to blood or body fluids, by health care personnel HepB vaccination and response status

HCP status	Postexposure testing		Postexposure prophylaxis		Postvaccination serologic testing
	Source patient (HBsAg)	HCP testing (anti-HBs)	HBIG	Vaccination	
Documented responder after complete series			No action needed		
Documented nonresponder after two complete series	Positive/unknown	—*	HBIG x2 separated by 1 month	—	N/A
	Negative		No action needed		
Response unknown after complete series	Positive/unknown	<10 mIU/mL	HBIG x1	Initiate revaccination	Yes
	Negative	<10 mIU/mL	None	Initiate revaccination	Yes
	Any result	≥10 mIU/mL	No action needed		
Unvaccinated/incompletely vaccinated or vaccine refusers	Positive/unknown	—	HBIG x1	Complete vaccination	Yes
	Negative	—	None	Complete vaccination	Yes

Abbreviations: anti HBs = antibody to hepatitis B surface antigen; HBIG = hepatitis B immune globulin; HBsAg = hepatitis B surface antigen; HCP = health care personnel; N/A = not applicable.

* Not indicated.

Prevaccination Serologic Testing

■ Recommended for:

- All persons born in Africa, Asia, the Pacific Islands, and other regions with HBsAg prevalence of 2% or higher
- Household, sex, and needle-sharing contacts of HBsAg-positive persons
- Men who have sex with men
- Injection drug users
- Certain persons receiving cytotoxic or immunosuppressive therapy

Postvaccination Serologic Testing

- **Serologic testing is NOT routinely recommended following vaccination of most persons**
- **Recommended for:**
 - Chronic hemodialysis patients
 - Other immunocompromised persons
 - Persons with HIV infection
 - Sex partners of HBsAg+ persons
 - Health care personnel

Revaccination

- Revaccination is generally not recommended for persons with a normal immune status
- Recommended for the following:
 - HBsAg-negative infants with anti-HBs <10 mIU/mL (born to HBsAg-positive mothers)
 - Hemodialysis patients
 - HIV-infected persons
 - Other immunocompromised persons

Vaccine Administration

■ Route: IM Injection

- Needle gauge: 22–25 gauge
- Needle length*: 5/8 – 1.5 inch depending on the patient's age and/or weight

■ Site*:

- Birth–11 months: Vastus lateralis muscle is preferred
- 1–3 years: Vastus lateralis muscle is preferred; deltoid muscle may be used if the muscle mass is adequate
- 4 years and older: Deltoid muscle is preferred; vastus lateralis muscle may be used

Vaccine Administration Considerations

- **Route: IM Injection**

- Administer HepB vaccine and HBIG (if needed) in different limbs

- **Site: NO BUTTS!**

Administration Errors	Count the Dose or Revaccinate?
Adult formulation administered to a child	Count the dose, if it meets minimum age and interval
Pediatric formulation administered to an adult	Dose does not count and should be repeated ASAP
HepA instead of HepB vaccine	Administer HepB vaccine ASAP

HepB Vaccine Contraindications and Precautions

■ Contraindication

- Severe allergic reaction to a vaccine component or following a prior dose

■ Precaution

- Moderate or severe acute illness

HepB Vaccine Adverse Reactions

Symptom

Frequency

Pain at injection site

3%-29%

Erythema

3%

Swelling

3%

Fever

1%-6%

Headache

3%

Severe systemic reactions

rare

Hepatitis B Vaccine Storage and Handling

- Store HepB-containing vaccines in a refrigerator between 2°C - 8°C (36°F - 46°F)
- DO NOT FREEZE
- Store in the original packaging with the lids closed in a clearly labeled bin and/or area of the storage unit
- Store pediatric and adult formulations separately, away from each other and other look- or sound-alike vaccines; e.g., HepA, Hib, HPV

HepB (Engerix-B)-Pediatric Formulation

Ages: Birth through 19 years
Use for: Any dose in the series
Route: Intramuscular (IM) injection

Read the package insert that accompanies the product to check for the presence of natural rubber or latex.

HepB (Recombivax HB)-Pediatric Formulation

Ages: Birth through 19 years
Use for: Any dose in the series
Route: Intramuscular (IM) injection

Vial stopper and syringe plunger stopper and tip contain latex

HepB (Engerix-B)-Adult Formulation

Ages: 20 years and older
Use for: Any dose in the series
Route: Intramuscular (IM) injection

Read the package insert that accompanies the product to check for the presence of natural rubber or latex.

HepB (Recombivax HB)-Adult Formulation

Ages: 20 years and older
Use for: Any dose in the series
Alternate Adolescent Schedule for 11 through 15 year olds:
Two 1 mL doses 4 to 6 months apart
Route: Intramuscular (IM) injection

Vial stopper and syringe plunger stopper and tip cap contain latex

4

Resources

Information for Parents: Hepatitis B and the Vaccine (Shot) to Prevent It

Hepatitis B and the Vaccine (Shot) to Prevent It

Last updated April 2017

The best way to protect against hepatitis B is by getting the hepatitis B vaccine. Doctors recommend that all children get the vaccine.

Why should my child get the hepatitis B shot?

The hepatitis B shot:

- Protects your child against hepatitis B, a potentially serious disease.
- Protects other people from the disease because children with hepatitis B usually don't have symptoms, but they may pass the disease to others without anyone knowing they were infected.
- Prevents your child from developing liver disease and cancer from hepatitis B.
- Keeps your child from missing school or childcare (and keeps you from missing work to care for your sick child).

Is the hepatitis B shot safe?

The hepatitis B vaccine is very safe, and it is effective at preventing hepatitis B. Vaccines, like any medicine, can have side effects. But serious side effects caused by the hepatitis B vaccine are extremely rare.

What are the side effects?

Most people who get the hepatitis B vaccine will have no side effects at all. When side effects do occur, they are often very mild, such as a low fever (less than 101 degrees) or a sore arm from the shot.

What is hepatitis B?

Hepatitis B is a contagious liver disease caused by the hepatitis B virus. When a person is first infected with the virus, he or she can develop an "acute" (short-term) infection. Acute hepatitis B refers to the first 6 months after someone is infected with the hepatitis B virus. This infection can range from a very mild illness with few or no symptoms to a serious condition requiring hospitalization. Some people are able to fight the infection and clear the virus.

For others, the infection remains and is "chronic," or lifelong. Chronic hepatitis B refers to the infection when it remains active instead of getting better after 6 months. Over time, the infection can cause serious health problems, and even liver cancer.



Doctors recommend that your child get 3 doses of the hepatitis B shot for best protection. Ask your doctor when your child should get the next shot. Typically, children get one dose at each of the following ages:

- Shortly after birth
- 1 through 2 months
- 6 through 18 months

Your child may get a 4th dose depending on the brand of vaccines the doctor uses.



Hepatitis B Standing Order Templates

Children and Adults

Standing orders for other vaccines are available at www.immunize.org/standing-orders.
 Note: This standing orders template may be adapted per a practice's discretion without obtaining permission from IAC. As a courtesy, please acknowledge IAC as its source.

STANDING ORDERS FOR Administering Hepatitis B Vaccine to Children and Teens

Purpose

To reduce morbidity and mortality from hepatitis B virus (HBV) by vaccinating all children and teens who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP).

Policy

Where allowed by state law, standing orders enable eligible nurses and other healthcare professionals (e.g., pharmacists) to assess the need for and vaccinate children and teens who meet any of the criteria below.

Procedure

- 1 Assess Children and Teens in Need of Vaccination against HBV infection based on the following criteria:
 - Lack of documentation of at least 3 doses of hepatitis B vaccine (HepB) with the third dose given at least 16 weeks after the first dose, at least 8 weeks after the second dose, and when no younger than age 24 weeks
- 2 Screen for contraindications and precautions

Contraindications

 - Do not give HepB to a child or teen who has experienced a serious reaction (e.g., anaphylaxis) to a prior dose of the vaccine or to any of its components. For information on vaccine components, refer to the manufacturers' package insert (www.immunize.org/packageinserts) or go to www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf.
 - Do not give any HepB to a child or teen who has experienced hypersensitivity to yeast.

Precautions

 - Moderate or severe acute illness with or without fever
- 3 Provide Vaccine Information Statements

Provide all patients (or, in the case of minors, their parent, or legal representative) with a copy of the most current federal Vaccine Information Statement (VIS). Provide non-English speaking patients with a copy of the VIS in their native language, if one is available and desired; these can be found at www.immunize.org/vis. (For information about how to document that the VIS was given, see section 6 titled "Document Vaccination.")
- 4 Prepare to Administer Vaccine

Choose the needle gauge, needle length, and injection site according to the following chart

AGE OF INFANT/CHILD/TEEN	NEEDLE LENGTH	INJECTION SITE
Newborns (1st 28 days)	5/8"	Anterolateral thigh muscle
Infants (1–12 months)	1"	Anterolateral thigh muscle
Toddlers (1–2 years)	1–1 1/4"	Anterolateral thigh muscle**
	5/8"–1"	Deltoid muscle of arm**
Children (3–10 years)	5/8"–1"	Deltoid muscle of arm**
	1–1 1/4"	Anterolateral thigh muscle
Adolescents and Teens (11–18 years)	5/8"–1"	Deltoid muscle of arm**
	1–1 1/2"	Anterolateral thigh muscle

* A 9/8" needle may be used for children for IM injection in the deltoid muscle only if the skin is stretched tight, the subcutaneous tissue is not bunched, and the injection is made at a 90-degree angle.
 ** Preferred site.

CONTINUED ON THE NEXT PAGE ►

Technical content reviewed by the Centers for Disease Control and Prevention
 IMMUNIZATION ACTION COALITION Saint Paul, Minnesota • 651-647-9009 • www.immunize.org • www.vaccineinformation.org
www.immunize.org/catg.d/p3076a.pdf • Item #P3076a (10/17)

Standing orders for other vaccines are available at www.immunize.org/standing-orders.
 Note: This standing orders template may be adapted per a practice's discretion without obtaining permission from IAC. As a courtesy, please acknowledge IAC as its source.

STANDING ORDERS FOR Administering Hepatitis B Vaccine to Adults

Purpose

To reduce morbidity and mortality from hepatitis B virus (HBV) by vaccinating all adults who meet the criteria established by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.

Policy

Where allowed by state law, standing orders enable eligible nurses and other health care professionals (e.g., pharmacists) to assess the need for vaccination and to vaccinate adults who meet any of the criteria below.

Procedure

- 1 Assess Adults for Need of Vaccination against HBV infection according to the following criteria:
 - Any person who wants to be protected from HBV infection
 - Patient with diabetes mellitus (Note: for those age 60 years or older with diabetes mellitus, at the discretion of the treating clinician)
 - Patient with end-stage renal disease, including patients receiving hemodialysis; HIV infection; or chronic liver disease
 - Sexually active and not in a long-term, mutually monogamous relationship (e.g., more than 1 sex partner during the previous 6 months)
 - Seeking evaluation or receiving treatment for a sexually transmitted infection (STI)
 - A male who has sex with males
 - A current or recent injection-drug user
 - At occupational risk of infection through exposure to blood or blood-contaminated body fluids (e.g., health care worker, public safety worker, trainee in a health professional or allied health school)
 - Residents or staff of an institution for persons with developmental disabilities
 - Sex partner or household member of a person who is chronically infected with HBV (HBsAg-positive). (This includes an HBsAg-positive adopted child.)
 - Planned travel to a country with high or intermediate prevalence of endemic HBV infection (for hepatitis B travel information from CDC, go to www.cdc.gov/travel/diseases/hepatitis-b)
 - People living in correctional facilities
 - All teenagers ages 18 and younger who are not fully vaccinated (see standing orders for children and teens at www.immunize.org/catg.d/p3076a.pdf)
- 2 Screen for Contraindications and Precautions

Contraindications

Do not give hepatitis B vaccine to a person who has experienced a serious systemic or anaphylactic reaction to a prior dose of the vaccine or to any of its components. For a list of vaccine components, refer to the manufacturer's package insert (www.immunize.org/packageinserts) or go to www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf.

Precautions

Moderate or severe acute illness with or without fever

CONTINUED ON THE NEXT PAGE ►

Technical content reviewed by the Centers for Disease Control and Prevention
 IMMUNIZATION ACTION COALITION Saint Paul, Minnesota • 651-647-9009 • www.immunize.org • www.vaccineinformation.org
www.immunize.org/catg.d/p3076.pdf • Item #P3076 (10/15)

- Ask the Experts–Hepatitis B FAQs:
www.immunize.org/askexperts/experts_hepb.asp
- CDC Viral Hepatitis–Hepatitis B Information:
www.cdc.gov/hepatitis/hbv/index.htm
- CDC Hepatitis B Vaccination:
www.cdc.gov/vaccines/vpd/hepb/index.html
- Hepatitis B and the Vaccine (Shot) to Prevent It–Information for Parents: www.cdc.gov/vaccines/parents/diseases/child/hepB-basics-color.pdf

- Hepatitis B Facts—Testing and Vaccination:
www.immunize.org/catg.d/p2110.pdf
- Hepatitis B and Health Care Personnel—FAQs:
www.immunize.org/catg.d/p2109.pdf
- Infection Prevention during Blood Glucose Monitoring and Insulin Administration: www.cdc.gov/injectionsafety/blood-glucose-monitoring.html
- Preexposure Evaluation for Health Care Personnel Previously Vaccinated with Complete ≥ 3 -Dose HepB Vaccine Series Who Have Not Had Postvaccination Serologic Testing (Figure 3):
www.cdc.gov/mmwr/volumes/67/rr/pdfs/rr6701-H.pdf